



Abstract

Enhancement of the antiproliferative effect of the abietane diterpenoid ferruginol by amination of position 18⁺

Natalia González-Zapata ¹, Lucinda Boyd ², Fatima Rivas ², Luying Shao ³, Jose M Prieto-Garcia ^{3,4}, 4

and Miguel A. González-Cardenete 1,* 5

6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	

Citation: González-Zapata, N.; Boyd, L.; Rivas, F.; Shao, L.; Prieto-23 Garcia, J. M.; González-Cardenete, 24 M. A. Antiproliferative optimization5 of the abietane diterpenoid ferruginol by introducing an amino group: 18-aminoferruginol. Med. Sci. Forum 2023, 2, x. https://doi.org/10.3390/xxxxx Academic Editor: Firstname Lastname Published: date

22

26

27

29

30

31

32

36

37

33 Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and insti-34 tutional affiliations. 35



Copyright: © 2023 by the author 38 Submitted for possible open access9 publication under the terms an 40 conditions of the Creative Commons Attribution (CC BY) licens**∉**1 (https://creativecommons.org/licens42 es/by/4.0/). 43

¹ Instituto de Tecnología Química, Universitat Politècnica de València-Consejo Superior de Investigaciones Científicas, Avda. de los Naranjos s/n, 46022 Valencia, Spain; natalia.gz6230@gmail.com (N.G.-Z.)

- Department of Chemistry, Lousiana State University, 133 Chopping Hall, Baton Rouge, Louisiana 70803, United States; frivas@lsu.edu (F.R.); lboyd18@lsu.edu (L.B.)
- ³ School of Pharmacy, University College London, London, United Kingdom; luying.shao.12@ucl.ac.uk
- Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, United Kingdom; j.m.prietogarcia@ljmu.ac.uk
- Correspondence: migoncar@itq.upv.es (M.A.G.-C.)
- + Presented at the 9th International Electronic Conference on Medicinal Chemistry, sciforum, 1-30 November 2023

Abstract: The family of abietane-type diterpenoids has long attracted natural product researchers, biochemists, organic and medicinal chemists with endless discoveries in terms of isolations, characterization, pharmacology, biosynthesis, chemical synthesis and medicinal chemistry. In our group, we have developed over the last decade a number of studies towards the semisynthesis of a variety of aromatic abietanes as well as biological screenings. The diterpene ferruginol is a very simple phenolic abietane which has demonstrated a plethora of promising biological and pharmacological properties. Some years ago, we developed a multigram semisynthetic procedure to obtain ferruginol itself from the commercially available (+)-dehydroabietylamine, also called leelamine. Over the years, we have investigated ferruginol and related analogues synthesized by us, with the aim of extending the pharmacological knowledge of this unique molecule and characteristic carbon framework and unveil their potential application. In this communication, we disclose how a simple modification in the carbon skeleton of ferruginol such as the introduction of an amino group can lead to a more potent analogue, 18-aminoferruginol or 12-hydroxydehydroabietylamine, in human breast cancer and melanoma cell lines and also changes in the mechanism of action as compared to the parent molecule. This outcome may set a platform for the development of novel anticancer agents based on natural products.

Keywords: Diterpene; abietanes; ferruginol; dehydroabietylamine; melanoma; breast cancer.

Author Contributions: Conceptualization, M.A.G.-C.; F.R., J.M.P.-G.; methodology, M.A.G.-C.; F.R., J.M.P.-G., L.S.; validation, F.R., J.M.P.-G.; formal analysis, M.A.G.-C., F.R., L.S.; investigation, M.A.G.-C., N.G.-Z., L.B., L.S.; resources, F.R.; writing-original draft preparation, M.A.G.-C.; writing-review and editing, M.A.G.-C.; F.R., J.M.P.-G., L.S., N.G.-Z., L.B.. All authors have read and agreed to the published version of the manuscript.

Funding: The funds were granted by the Board of Regents Support Fund Award LEQSF-RD-A-05.

Acknowledgments: We would like to thank Dept Pharmaceutics for allowing some lab experiments to be conducted in his cell lab at the School of Pharmacy, UCL.

Conflicts of Interest: The authors declare no conflict of interest.